MARKET

INCY

INCY

Incyte Corp
NASDAQ
115.75
+0.66
+0.57%
Opening 13:23 07/16 EDT
OPEN
115.06
PREV CLOSE
115.09
HIGH
117.18
LOW
114.13
VOLUME
579.20K
TURNOVER
--
52 WEEK HIGH
118.97
52 WEEK LOW
67.17
MARKET CAP
23.12B
P/E (TTM)
16.36
1D
5D
1M
3M
1Y
5Y
1D
What to Expect From Incyte's Q2 2026 Earnings Report
Barchart · 1d ago
INCYTE <INCY.O>: BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $136 FROM $124
Reuters · 1d ago
Analysts Are Bullish on Top Healthcare Stocks: Incyte (INCY), Annexon Biosciences (ANNX)
TipRanks · 1d ago
A Fresh Look At Syndax Pharmaceuticals
Seeking Alpha · 2d ago
Incyte Now #400 Largest Company, Surpassing Weyerhaeuser
NASDAQ · 2d ago
Incyte: Early Strength in VGA039 Offsets Execution Risks; Salveen Richter Reiterates Hold and $100 Price Target
TipRanks · 2d ago
Incyte Is Maintained at Overweight by Barclays
Dow Jones · 2d ago
INCYTE CORPORATION <INCY.O>: BARCLAYS RAISES TARGET PRICE TO $134 FROM $117
Reuters · 2d ago
More
About INCY
Incyte Corporation is a biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics. It operates in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity. Its hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs. Its oncology franchise includes two approved products, PEMAZYRE (pemigatinib) and ZYNYZ (retifanlimab-dlwr), as well as several clinical development programs. Its Inflammation and Autoimmunity franchise consists of one approved product, OPZELURA (ruxolitinib) cream, with several clinical programs in development. It also includes VGA039, a novel monoclonal antibody in Phase III development for von Willebrand disease (VWD). It manages business activities through the development and commercialization of oncology and dermatology products.

Webull offers Incyte Corp stock information, including NASDAQ: INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.